Approval · Notice of Compliance 21898 · 2019
VIZIMPRO: Notice of Compliance 21898
Issued February 26, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21898
- Date
- February 26, 2019
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- DACOMITINIB 15 MG per TAB
- DACOMITINIB 30 MG per TAB
- DACOMITINIB 45 MG per TAB